narvikk
- Goldman Sachs upgraded MoonLake Immunotherapeutics (NASDAQ:MLTX) to buy from neutral citing likely positive phase 3 results mid-year from hidradenitis suppurativa candidate sonelokimab.
- The investment bank has a price target of $82 (~88% upside based on Jan. 16 close).
- Analyst Richard